Drew Elizabeth McCormick

Subscribe to Drew Elizabeth McCormick's Posts
Drew Elizabeth McCormick maintains a general health industry and regulatory practice. Drew advises health care clients on a wide variety of health care regulatory issues, including Medicare and Medicaid regulations, the Federal Anti-Kickback Statute, Ethics in Patient Referral Law, False Claims Act and Health Insurance Portability and Accountability Act (HIPAA), as well as state fraud and abuse laws, privacy laws, licensure regulation, research regulation, and health care compliance matters. Drew also has experience counseling clients who are undergoing government audits and investigations. Read Drew Elizabeth McCormicks' full bio.

Departments Issue Final Rule Implementing Certain No Surprises Act Provisions


By , , and on Sep 14, 2022
Posted In Employee Benefits, Health and Welfare Plans

On August 19, 2022, the US Departments of Health and Human Services (HHS), Labor and Treasury posted a final rule revising portions of the federal No Surprises Act (NSA). Generally, the rule finalizes three aspects of the two-part interim final rule that the Departments published along with the Office of Personnel Management in 2021. First,...

Continue Reading



Supreme Court Agrees to Review Medicare Payment Cuts to 340B Drugs


By and on Oct 19, 2021
Posted In Employee Benefits, Health and Welfare Plans

The US Supreme Court announced in July that it will take up review of the decision by the US Court of Appeals for the District of Columbia Circuit upholding Medicare’s 2018 payment cuts to 340B drugs. The case will be closely watched, given its potentially far-reaching impacts on reimbursements to most hospitals that participate in...

Continue Reading



Court Issues Permanent Injunction Blocking Medicare 340B Payment Cuts


By , , and on Jan 22, 2019
Posted In Employee Benefits, Health and Welfare Plans

The US District Court for the District of Columbia recently held that the Centers for Medicare and Medicaid Services (CMS) exceeded its authority by reducing Medicare payment rates for 340B drugs, but, because of the budget-neutral nature of the cuts, the court left implementation details of its order temporarily unresolved to avoid disrupting administration of...

Continue Reading



STAY CONNECTED

TOPICS

ARCHIVES

Top ranked chambers 2022
US leading firm 2022